Radiolabelled RGD peptides for imaging and therapy

Area of Science:

• Molecular imaging
• Oncology
• Radiopharmaceutical science

Background:

• Angiogenesis imaging is crucial for evaluating antiangiogenic therapies like bevacizumab.
• Non-invasive assessment of angiogenic activity aids in treatment response evaluation.
• Integrin α(v)β(3) is a key molecular marker of the angiogenic cascade.

Purpose of the Study:

• To review current data on imaging integrin α(v)β(3) expression using radiolabeled RGD peptides.
• To focus on tracers currently in clinical use for angiogenesis imaging.
• To present future perspectives on clinical applications of radiolabeled RGD peptides, including radionuclide therapy.

Main Methods:

• Review of current literature on radiolabeled RGD peptides for imaging integrin α(v)β(3).
• Focus on tracers that have achieved clinical translation.
• Analysis of data related to clinical use and potential therapeutic applications.

Main Results:

• Radiolabeled peptides targeting integrin α(v)β(3) represent a clinically validated approach for angiogenesis imaging.
• Several RGD peptide-based tracers are in clinical use for molecular imaging.
• The review summarizes existing clinical data and ongoing research.

Conclusions:

• Radiolabeled RGD peptides are a valuable tool for non-invasive angiogenesis imaging and therapy response assessment.
• Future applications may include radionuclide therapy for targeting α(v)β(3)-expressing tumors.
• Continued research will expand the clinical utility of these targeted radiotracers.